Ledger · 2026-08-29 · Biotechnology / Food Safety
Commercial Production of Pediocin PA-1 Biopreservative via Low-CapEx Fermentation
Cleared
This concept cleared all seven gates and every voiding sub-test.
| Incumbent displaced | Nisin (E234) |
| Measured advantage | 22x lower IC50 against Listeria monocytogenes compared to Nisin (0.10-7.34 ng/mL vs 2.2-781 ng/mL) |
| Time to first revenue | 6 months |
| Gross margin at parity | 69.4% |
| Startup CapEx | $185,000 |
The full analysis goes to the list
Mechanism, operating protocol with real conditions and yields, computed unit economics with a six-scenario stress test, the absence audit, and every resolved citation.
Assessed 2026-08-29 against seven gates plus the voiding sub-tests. How the method works · Browse all concepts